Tonix Pharmaceuticals Holding Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Tonix Pharmaceuticals Holding kazanç ve gelirinin sırasıyla yıllık 27.2% ve 42.7% oranında artması tahmin edilirken, EPS'nin yıllık 52.9% oranında büyümesi bekleniyor.

Anahtar bilgiler

27.2%

Kazanç büyüme oranı

52.90%

EPS büyüme oranı

Biotechs kazanç büyümesi	24.4%
Gelir büyüme oranı	42.7%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	27 Jul 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Seeking Alpha • Jun 29

Tonix: Slow Start For Tonmya, Speculative Pipeline Warrants Hold Rating

Summary Tonix Pharmaceuticals remains rated Hold as Tonmya's commercial launch underwhelms, with Q1 2026 net product revenue at $3.7m, arguably below expectations. TNXP's cash runway is limited, with $185.5m on hand and quarterly net losses exceeding $40m, raising future funding concerns. Competitive pressure and uncertain pipeline prospects, including MDD and Lyme disease candidates, temper confidence in TNXP's ability to drive meaningful upside. I maintain a Hold, seeing limited near-term catalysts but potential upside if Tonmya sales accelerate or pipeline assets deliver unexpected positive data. Read the full article on Seeking Alpha

Analiz Makalesi • Dec 01

Will Tonix Pharmaceuticals Holding (NASDAQ:TNXP) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Analiz Makalesi • Aug 14

Here's Why We're Not Too Worried About Tonix Pharmaceuticals Holding's (NASDAQ:TNXP) Cash Burn Situation

NasdaqCM:TNXP 1 Year Share Price vs Fair Value Explore Tonix Pharmaceuticals Holding's Fair Values from the Community...

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:TNXP - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2028	163	-85	-170	-137	4
12/31/2027	79	-152	-205	-152	4
12/31/2026	34	-170	-200	-144	4
3/31/2026	18	-147	-131	-126	N/A
12/31/2025	13	-124	-103	-100	N/A
9/30/2025	10	-99	-76	-75	N/A
6/30/2025	10	-81	-65	-65	N/A
3/31/2025	10	-132	-60	-60	N/A
12/31/2024	10	-130	-61	-61	N/A
9/30/2024	11	-135	-69	-69	N/A
6/30/2024	12	-149	-76	-73	N/A
3/31/2024	10	-99	-91	-87	N/A
12/31/2023	8	-117	-110	-102	N/A
9/30/2023	4	-123	-114	-102	N/A
6/30/2023	N/A	-124	-121	-102	N/A
3/31/2023	N/A	-123	-132	-100	N/A
12/31/2022	N/A	-117	-146	-98	N/A
9/30/2022	N/A	-112	-167	-98	N/A
6/30/2022	N/A	-102	-156	-88	N/A
3/31/2022	N/A	-98	-141	-86	N/A
12/31/2021	N/A	-92	-111	-76	N/A
9/30/2021	N/A	-80	-81	-67	N/A
6/30/2021	N/A	-73	-80	-69	N/A
3/31/2021	N/A	-64	-69	-60	N/A
12/31/2020	N/A	-52	-57	-49	N/A
9/30/2020	N/A	-46	-45	-41	N/A
6/30/2020	N/A	-42	-33	-33	N/A
3/31/2020	N/A	-34	-27	-27	N/A
12/31/2019	N/A	-31	N/A	-27	N/A
9/30/2019	N/A	-31	N/A	-27	N/A
6/30/2019	N/A	-28	N/A	-25	N/A
3/31/2019	N/A	-29	N/A	-26	N/A
12/31/2018	N/A	-29	N/A	-24	N/A
9/30/2018	N/A	-24	N/A	-22	N/A
6/30/2018	N/A	-24	N/A	-22	N/A
3/31/2018	N/A	-23	N/A	-21	N/A
12/31/2017	N/A	-21	N/A	-19	N/A
9/30/2017	N/A	-23	N/A	-20	N/A
6/30/2017	N/A	-25	N/A	-23	N/A
3/31/2017	N/A	-30	N/A	-27	N/A
12/31/2016	N/A	-39	N/A	-37	N/A
9/30/2016	N/A	-45	N/A	-44	N/A
6/30/2016	N/A	-50	N/A	-48	N/A
3/31/2016	N/A	-52	N/A	-49	N/A
12/31/2015	N/A	-48	N/A	-43	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: TNXP önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: TNXP önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: TNXP önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: TNXP şirketinin gelirinin (yıllık 42.7% ) US pazarından (yıllık 12.5% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: TNXP şirketinin gelirinin (yıllık 42.7% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: TNXP 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/07/28 19:58
Gün Sonu Hisse Fiyatı	2026/07/28 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Tonix Pharmaceuticals Holding Corp. 11 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
James Molloy	Alliance Global Partners
Chiara Russo	Brean Capital Historical (Janney Montgomery)
David Buck	B. Riley Securities, Inc.

Tonix Pharmaceuticals Holding Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus revenue estimates decrease by 58%

Forecast to breakeven in 2028

Consensus revenue estimates increase by 21%

Forecast to breakeven in 2028

Price target decreased by 20% to US$54.33

Consensus EPS estimates upgraded to US$13.03 loss

Recent updates

Tonix Pharmaceuticals Holding Corp. to Report Q2, 2026 Results on Aug 10, 2026

New minor risk - Share price stability

Tonix Pharmaceuticals Holding Corp. Announces Retirement of Gregory M. Sullivan as Chief Medical Officer, Effective August 20, 2026

Tonix Pharmaceuticals Advances Tnx-801 Live Attenuated Minimally Replicative Investigational Vaccine Candidate Based on Horsepox Virus to Protect Against Mpox Disease

Tonix Pharmaceuticals Holding Corp. Announces Major Managed Medicare Agreement for Tonmya and Expands Pharmacy Coverage

Tonix Pharmaceuticals Enrolls First Patient in Phase 2 Study for Major Depressive Disorder

Tonix Pharmaceuticals Holding Corp Announces First Patient Enrolled in Phase 2 Horizon Study of TNX-102 SL For Major Depressive Disorder

Tonix: Slow Start For Tonmya, Speculative Pipeline Warrants Hold Rating

Co-Founder recently bought US$59k worth of stock

Tonix Pharmaceuticals Holding Corp. Announces Publication Of Phase 1 Clinical Data Of TNX-1500 Fc-Modified Anti-CD40L Monoclonal Antibody

Tonix Pharmaceuticals Presents Real-World Claims Analysis And Launches TONMYA For Fibromyalgia Treatment

Consensus revenue estimates decrease by 58%

New minor risk - Share price stability

New minor risk - Profitability

Forecast to breakeven in 2028

Consensus revenue estimates increase by 21%

New minor risk - Profitability

Tonix Pharmaceuticals Holding Corp. Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of Tnx-4800

Co-Founder recently bought US$63k worth of stock

New minor risk - Share price stability

Tonix Pharmaceuticals Holding Corp Presents Phase 1 Data And Outlines Planned Adaptive Phase 2 Field Study Of TNX-4800 For Prevention Of Lyme Disease

Tonix Pharmaceuticals Holding Corp Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900

Forecast to breakeven in 2028

Tonix Pharmaceuticals Holding Corp., Annual General Meeting, May 07, 2026

Co-Founder recently bought US$223k worth of stock

Price target decreased by 20% to US$54.33

Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Revenue and earnings growth

Tonix Pharmaceuticals Presents Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia

Tonix Pharmaceuticals Holding Corp Announces Publication of Clinical Pharmacokinetic Studies of TONMYA and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development

New minor risk - Share price stability

Tonix Pharmaceuticals Holding Corp. Presents Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) At the 2026 Non-Opioid Pain Therapeutics Summit

Tonix Pharmaceuticals Holding Corp. Announces Program Updates on Tnx-4800 Product Candidate for Protection Against Lyme Disease

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering in the amount of $19.999998 million.

Tonix Pharmaceuticals Holding Corp. Appoints Irina Ishak as General Counsel, Effective December 8, 2025

Consensus EPS estimates upgraded to US$13.03 loss

Will Tonix Pharmaceuticals Holding (NASDAQ:TNXP) Spend Its Cash Wisely?

Tonix Pharmaceuticals Holding Corp. Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder

Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA (Cybobenzaprine HCl Sublingual Tablets) as A First-In-Class Fibromyalgia Treatment

Third quarter 2025 earnings: EPS in line with analyst expectations despite revenue beat

Tonix Pharmaceuticals Holding Corp. Presents Data on Tonmya at the 2025 American College of Rheumatology Convergence

Tonix Pharmaceuticals Holding Corp. Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital

Tonix Pharmaceuticals Holding Corp. Presents Data on TNX-801 Mpox Vaccine at World Vaccine Congress-Europe 2025

Tonix Pharmaceuticals Holding Corp. Appoints Ganesh Kamath as Head of Market Access, Effective September 29, 2025

Tonix Pharmaceuticals Holding Corp. Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of Tnx-2900 (Intranasal Potentiated Oxytocin) in 2026

Tonix Pharmaceuticals Holding Corp. Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder

Tonix Pharmaceuticals Holding Corp. Presents Clinical Data on Tonmya for the Treatment of Fibromyalgia at PAINWEEK 2025

Tonix Pharmaceuticals Holding Corp. Announces FDA Approval of Tonmya (cyclobenzaprine HCl Sublingual Tablets) for the Treatment of Fibromyalgia

Here's Why We're Not Too Worried About Tonix Pharmaceuticals Holding's (NASDAQ:TNXP) Cash Burn Situation

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

New major risk - Share price stability

Tonix Pharmaceuticals Holding Corp. to Report Q2, 2025 Results on Aug 11, 2025

Tonix Pharmaceuticals Holding Corp. Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025

Tonix Pharmaceuticals Holding Corp. Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models

High number of new directors

Tonix Pharmaceuticals Holding Corp. Appoints James ‘Jim’ Hunter to Board of Directors, Effective June 12, 2025

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering in the amount of $150 million.

Consensus revenue estimates increase by 15%

Tonix Pharmaceuticals Holding Corp. Announces First Patient Dosed in Phase 2 Oasis Study of TNX-102 SL for Reduction of Acute Stress Response

Consensus EPS estimates upgraded to US$12.40 loss, revenue downgraded

Co-Founder recently bought US$86k worth of stock

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 88% to US$60.00

Tonix Pharmaceuticals Holding Corp. Presents Data on Potential Mpox Vaccine TNX-801 at World Vaccine Washington 2025

Tonix Pharmaceuticals Holding Corp. Presents Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia At the American Academy of Pain Medicine 2025 Annual Meeting

Tonix Pharmaceuticals Holding Corp. Launches Tonix One™, A Fully-Integrated Digital Platform Designed to Help Patients Better Understanding and Manage Their Migraine Condition

Tonix Pharmaceuticals Holding Corp. Announces U.S. Food and Drug Administration to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia

Tonix Pharmaceuticals Announces Grant by Medical CBRN Defense Consortium (MCDC) for Development of TNX-801, the Company’s Single-Dose Mpox and Smallpox Vaccine Candidate

Tonix Pharmaceuticals Holding Corp. Presents Data and Analyses of Tnx-102 Sl Treatment Effects on Fibromyalgia At 7Th International Congress on Cont Cont Cont Cont Cont Cont Contconties in Fibromyalgia